LISTEN TO THE EXPERTS

Christopher Mantyh, MD
Colorectal surgeon
Associate Professor of Surgery/Chief, Gastrointestinal and Colorectal Surgery at Duke University Medical Center

Learn about Dr. Mantyh's clinical use of OFIRMEV and link to hear other experiences from your peers

LISTEN TO THE EXPERTS

Chris Pasero, MS, RN-BC, FAAN
Pain management educator

Learn about the clinical use of OFIRMEV from pain management educator Chris Pasero and link to hear more from your peers

LESS PAIN

Take a closer look at the clinical data from
Pain Study 1

LESS OPIOIDS

See how OFIRMEV + PCA morphine significantly reduced morphine consumption vs placebo + PCA morphine¹

Indication

OFIRMEV (acetaminophen) injection is indicated for the management of mild to moderate pain; the management of moderate to severe pain with adjunctive opioid analgesics; and the reduction of fever.

Important Safety Information

OFIRMEV is contraindicated in patients with severe hepatic impairment, severe active liver disease or with known hypersensitivity to acetaminophen or to any of the excipients in the formulation. Acetaminophen should be used with caution in patients with the following conditions: hepatic impairment or active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment.

Do not exceed the maximum recommended daily dose of acetaminophen. Administration of acetaminophen by any route in doses higher than recommended may result in hepatic injury, including the risk of severe hepatotoxicity and death.

OFIRMEV should be administered only as a 15-minute intravenous infusion.

Discontinue OFIRMEV immediately if symptoms associated with allergy or hypersensitivity occur. Do not use in patients with acetaminophen allergy.

The most common adverse reactions in patients treated with OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in pediatric patients.

OFIRMEV is approved for use in patients ≥2 years of age.

The antipyretic effects of OFIRMEV may mask fever in patients treated for postsurgical pain.

To report SUSPECTED ADVERSE REACTIONS, contact Cadence Pharmaceuticals Inc. at 1‑877‑647‑2239 or FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch.

References: 1. Sinatra RS, Jahr JS, Reynolds LW, Viscusi ER, Groudine SB, Payen-Champenois C. Efficacy and safety of single and repeated administration of 1 gram intravenous acetaminophen injection (paracetamol) for pain management after major orthopedic surgery. Anesthesiology. 2005;102:822-831. 2. Data on file. Cadence Pharmaceuticals, Inc. 3. Wininiger SJ, Miller H, Minkowitz HS, et al. A randomized, double-blind, placebo-controlled, multicenter, repeat-dose study of two intravenous acetaminophen dosing regimens for the treatment of pain after abdominal laparoscopic surgery. Clin Ther. 2010;32:2348-2369. 4. American Society of Anesthesiologists Task Force on Acute Pain Management. Practice guidelines for acute pain management in the perioperative setting. Anesthesiology. 2012;116:248-273. 5. Crews JC. Multimodal pain management strategies for office-based and ambulatory procedures. JAMA. 2002;288:629-632. 6. OFIRMEV^® (acetaminophen) injection prescribing information. Cadence Pharmaceuticals, Inc. 7. Memis D, Inal MT, Kavalci G, Sezer A, Sut N. Intravenous paracetamol reduced the use of opioids, extubation time, and opioid-related adverse effects after major surgery in intensive care unit. J Crit Care. 2010;25:458-462. 8. Atef A, Fawaz AA. Intravenous paracetamol is highly effective in pain treatment after tonsillectomy in adults. Eur Arch Otorhinolaryngol. 2008;265:351-355. 9. Kett DH, Breitmeyer JB, Ang R, Royal MA. A randomized study of the efficacy and safety of intravenous acetaminophen vs. intravenous placebo for the treatment of fever. Clin Pharmacol Ther. 2011;90:32-39.